The global demand for Antitussive Drugs Market is presumed to reach the market size of nearly USD 2374.27 Million by 2032 from USD 1495.51 Million in 2023 with a CAGR of 5.27% under the study period 2024-2032.
Antitussive drugs are a class of heterogeneous medications generally used to suppress dry cough in patients suffering from respiratory disorders. Antitussive drugs can cure various symptoms caused by the common cold, flu, allergies, hay fever, or other breathing disorders like sinusitis, bronchitis, etc. These drugs reduce the urge to cough in patients by acting on the cough center in the brain. They are either opiates or opioids like pholcodine, codeine, and dextromethorphan. One of the most used over-the-counter antitussive drugs is Dextromethorphan, and it is relatively safe. They are taken orally and are available in the form of syrup, tablets, or vapor. These drugs are not suitable for long-term use since they risk abuse and may even cause addiction.
MARKET DYNAMICS
A high rate of atmospheric pollution and the growing prevalence of respiratory disorders among the global population is the central stimulant for the growth of the cough suppressants market. The contagious nature of individual coughs and cough being a significant unmet medical need will further propel market growth. The demand for antitussive drugs will see a steady increase since persistent cough can harm a person's quality of life. Rising awareness and easy availability of these drugs will benefit market growth. Continuing research to produce cheap, effective cough suppressants with minimal side effects will hinder this market's growth.
The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Antitussive Drugs. The growth and trends of Antitussive Drugs industry provide a holistic approach to this study.
MARKET SEGMENTATION
This section of the Antitussive Drugs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
By Indication
Pain
Cold
Cough
Others
By Drug Class
Peripherally Acting Drugs
Centrally Acting Drugs
Others
By Drug
Dextromethorphan
Benzonatate
By Dosage Form
Tablets
Syrup
Others
REGIONAL ANALYSIS
This section covers the regional outlook, which accentuates current and future demand for the Antitussive Drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Antitussive Drugs market include Pfizer Inc., Johnson & Johnson, Sanofi S.A., GlaxoSmithKline Plc, Merck & Co. Inc., Novartis International AG, AstraZeneca Plc, Boehringer Ingelheim International GmbH, Roche Holding AG, Bayer AG, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Mylan N.V., Cipla Ltd., Reckitt Benckiser Group Plc, Perrigo Company Plc, Glenmark Pharmaceuticals Ltd. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.
3.7.1 Market Attractiveness Analysis By Indication
3.7.2 Market Attractiveness Analysis By Drug Class
3.7.3 Market Attractiveness Analysis By Drug
3.7.4 Market Attractiveness Analysis By Dosage Form
3.7.5 Market Attractiveness Analysis By Region
4. VALUE CHAIN ANALYSIS
4.1. Value Chain Analysis
4.2. Raw Material Analysis
4.2.1 List of Raw Materials
4.2.2 Raw Material Manufactures List
4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
4.4.1 Direct Marketing
4.4.2 Indirect Marketing
4.4.3 Marketing Channel Development Trend
5. GLOBAL ANTITUSSIVE DRUGS MARKET ANALYSIS BY INDICATION
5.1. Overview By Indication
5.2. Historical and Forecast Data
5.3. Analysis By Indication
5.4. Pain Historic and Forecast Sales By Regions
5.5. Cold Historic and Forecast Sales By Regions
5.6. Cough Historic and Forecast Sales By Regions
5.7. Others Historic and Forecast Sales By Regions
6. GLOBAL ANTITUSSIVE DRUGS MARKET ANALYSIS BY DRUG CLASS
6.1. Overview By Drug Class
6.2. Historical and Forecast Data
6.3. Analysis By Drug Class
6.4. Peripherally Acting Drugs Historic and Forecast Sales By Regions
6.5. Centrally Acting Drugs Historic and Forecast Sales By Regions
6.6. Others Historic and Forecast Sales By Regions
7. GLOBAL ANTITUSSIVE DRUGS MARKET ANALYSIS BY DRUG
7.1. Overview By Drug
7.2. Historical and Forecast Data
7.3. Analysis By Drug
7.4. Dextromethorphan Historic and Forecast Sales By Regions
7.5. Benzonatate Historic and Forecast Sales By Regions
8. GLOBAL ANTITUSSIVE DRUGS MARKET ANALYSIS BY DOSAGE FORM
8.1. Overview By Dosage Form
8.2. Historical and Forecast Data
8.3. Analysis By Dosage Form
8.4. Tablets Historic and Forecast Sales By Regions
8.5. Syrup Historic and Forecast Sales By Regions
8.6. Others Historic and Forecast Sales By Regions
9. GLOBAL ANTITUSSIVE DRUGS MARKET ANALYSIS BY GEOGRAPHY
9.1. Regional Outlook
9.2. Introduction
9.3. North America Sales Analysis
9.3.1 Overview, Historic and Forecast Data Sales Analysis
9.3.2 North America By Segment Sales Analysis
9.3.3 North America By Country Sales Analysis
9.3.4 United States Sales Analysis
9.3.5 Canada Sales Analysis
9.3.6 Mexico Sales Analysis
9.4. Europe Sales Analysis
9.4.1 Overview, Historic and Forecast Data Sales Analysis
9.4.2 Europe By Segment Sales Analysis
9.4.3 Europe By Country Sales Analysis
9.4.4 United Kingdom Sales Analysis
9.4.5 France Sales Analysis
9.4.6 Germany Sales Analysis
9.4.7 Italy Sales Analysis
9.4.8 Russia Sales Analysis
9.4.9 Rest Of Europe Sales Analysis
9.5. Asia Pacific Sales Analysis
9.5.1 Overview, Historic and Forecast Data Sales Analysis
9.5.2 Asia Pacific By Segment Sales Analysis
9.5.3 Asia Pacific By Country Sales Analysis
9.5.4 China Sales Analysis
9.5.5 India Sales Analysis
9.5.6 Japan Sales Analysis
9.5.7 South Korea Sales Analysis
9.5.8 Australia Sales Analysis
9.5.9 South East Asia Sales Analysis
9.5.10 Rest Of Asia Pacific Sales Analysis
9.6. Latin America Sales Analysis
9.6.1 Overview, Historic and Forecast Data Sales Analysis
9.6.2 Latin America By Segment Sales Analysis
9.6.3 Latin America By Country Sales Analysis
9.6.4 Brazil Sales Analysis
9.6.5 Argentina Sales Analysis
9.6.6 Peru Sales Analysis
9.6.7 Chile Sales Analysis
9.6.8 Rest of Latin America Sales Analysis
9.7. Middle East & Africa Sales Analysis
9.7.1 Overview, Historic and Forecast Data Sales Analysis
9.7.2 Middle East & Africa By Segment Sales Analysis
9.7.3 Middle East & Africa By Country Sales Analysis
9.7.4 Saudi Arabia Sales Analysis
9.7.5 UAE Sales Analysis
9.7.6 Israel Sales Analysis
9.7.7 South Africa Sales Analysis
9.7.8 Rest Of Middle East And Africa Sales Analysis
10. COMPETITIVE LANDSCAPE OF THE ANTITUSSIVE DRUGS COMPANIES
10.1. Antitussive Drugs Market Competition
10.2. Partnership/Collaboration/Agreement
10.3. Merger And Acquisitions
10.4. New Product Launch
10.5. Other Developments
11. COMPANY PROFILES OF ANTITUSSIVE DRUGS INDUSTRY
11.1. Top Companies Market Share Analysis
11.2. Market Concentration Rate
11.3. Pfizer Inc.
11.3.1 Company Overview
11.3.2 Company Revenue
11.3.3 Products
11.3.4 Recent Developments
11.4. Johnson & Johnson
11.4.1 Company Overview
11.4.2 Company Revenue
11.4.3 Products
11.4.4 Recent Developments
11.5. Sanofi S.A.
11.5.1 Company Overview
11.5.2 Company Revenue
11.5.3 Products
11.5.4 Recent Developments
11.6. GlaxoSmithKline Plc
11.6.1 Company Overview
11.6.2 Company Revenue
11.6.3 Products
11.6.4 Recent Developments
11.7. Merck & Co. Inc.
11.7.1 Company Overview
11.7.2 Company Revenue
11.7.3 Products
11.7.4 Recent Developments
11.8. Novartis International AG
11.8.1 Company Overview
11.8.2 Company Revenue
11.8.3 Products
11.8.4 Recent Developments
11.9. AstraZeneca Plc
11.9.1 Company Overview
11.9.2 Company Revenue
11.9.3 Products
11.9.4 Recent Developments
11.10. Boehringer Ingelheim International GmbH
11.10.1 Company Overview
11.10.2 Company Revenue
11.10.3 Products
11.10.4 Recent Developments
11.11. Roche Holding AG
11.11.1 Company Overview
11.11.2 Company Revenue
11.11.3 Products
11.11.4 Recent Developments
11.12. Bayer AG
11.12.1 Company Overview
11.12.2 Company Revenue
11.12.3 Products
11.12.4 Recent Developments
11.13. Teva Pharmaceutical Industries Ltd.
11.13.1 Company Overview
11.13.2 Company Revenue
11.13.3 Products
11.13.4 Recent Developments
11.14. Sun Pharmaceutical Industries Ltd.
11.14.1 Company Overview
11.14.2 Company Revenue
11.14.3 Products
11.14.4 Recent Developments
11.15. Mylan N.V.
11.15.1 Company Overview
11.15.2 Company Revenue
11.15.3 Products
11.15.4 Recent Developments
11.16. Cipla Ltd.
11.16.1 Company Overview
11.16.2 Company Revenue
11.16.3 Products
11.16.4 Recent Developments
11.17. Reckitt Benckiser Group Plc
11.17.1 Company Overview
11.17.2 Company Revenue
11.17.3 Products
11.17.4 Recent Developments
11.18. Perrigo Company Plc
11.18.1 Company Overview
11.18.2 Company Revenue
11.18.3 Products
11.18.4 Recent Developments
11.19. Glenmark Pharmaceuticals Ltd
11.19.1 Company Overview
11.19.2 Company Revenue
11.19.3 Products
11.19.4 Recent Developments
Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies